FDG-PET staging and importance of lymph node SUV in head and neck cancer
Open Access
- 16 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Head & Neck Oncology
- Vol. 2 (1), 19
- https://doi.org/10.1186/1758-3284-2-19
Abstract
The role of positron emission tomography (PET) with fluoro-deoxy-glucose (FDG) in the staging of head and neck cancer (HNC) is unclear. The NCCN guidelines do not recommend FDG-PET as a part of standard workup. The purpose of this report is to examine the role of FDG-PET imaging in altering management and providing prognostic information for HNC. Retrospective review of HNC patients who had a staging FDG-PET scan performed at either Thomas Jefferson University or University of Kansas Medical Center between the years 2001 and 2007. A total of 212 PET scans were performed in patients who went on to receive radiotherapy. The median follow-up time for all patients was 469 days. The PPV and NPV of PET imaging to correctly identify lymph node status was 94% and 89% respectively. Lymph nodes with extracapsular extension (ECE) had higher SUVs than nodes without ECE, 11.0 vs. 5.0 (p < 0.0007). Maximum SUV for the primary tumor > 8.0 was predictive of worse overall survival (p < 0.045), while the SUV of the lymph nodes was predictive for distant recurrence at one year--with a mean SUV value of 10.4 for patients with distant failure vs. 7.0 without (p < 0.05). FDG-PET staging in head and neck cancer has good positive and negative predictive values in determining lymph node status. The maximum SUV of the primary tumor is predictive of overall survival. This is the first report to find that the SUV of a lymph node is predictive for ECE and also for distant recurrence.Keywords
This publication has 36 references indexed in Scilit:
- Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG AnalysisJournal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- 2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynxEuropean Journal of Surgical Oncology, 2007
- Impact of [18F]‐2‐Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography on Previously Untreated Head and Neck Cancer PatientsThe Laryngoscope, 2007
- The chemoradiation paradigm in head and neck cancerNature Clinical Practice Oncology, 2007
- Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative NeckJournal of Clinical Oncology, 2006
- PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patientsInternational Journal of Clinical Oncology, 2006
- Use, Accuracy, and Implications for Patient Management of [18F]-2-Fluorodeoxyglucose-Positron Emission/Computerized Tomography for Head and Neck TumorsThe Laryngoscope, 2005
- Sentinel node biopsy in oral cavity cancer: Correlation with PET scan and immunohistochemistryHead & Neck, 2002
- Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Histopathologic Correlation in the Initial Staging of Head and Neck CancerAnnals of Surgery, 2002